2026-04-29T19:34:49Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/170832024-11-28T14:58:34Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16963col_20.500.12105_16966col_20.500.12105_16985

00925njm 22002777a 4500 dc Montes, Ariana author Perez-Pampin, Eva author Navarro-Sarabia, Federico author Moreira, Virginia author Rodríguezde la Serna, Arturo author Magallares, Berta author Vasilopoulos, Yiannis author Sarafidou, Theologia author Fernández-Nebro, Antonio author Ordóñez, María Del Carmen author Narváez, Javier author Cañete, Juan D author Marquez, Ana author Pascual-Salcedo, Dora author Joven, Beatriz author Carreira, Patricia author Moreno-Ramos, Manuel J author Caliz, Rafael author Ferrer, Miguel Angel author Garcia-Portales, Rosa author Blanco, Francisco J author Magro, Cesar author Raya, Enrique author Valor, Lara author Alegre-Sancho, Juan J author Balsa, Alejandro author Martin, Javier author Plant, Darren author Isaacs, John author Morgan, Ann W author Barton, Anne author Wilson, Anthony G author Gómez-Reino, Juan J author Gonzalez, Antonio author 2015-03-18 INTRODUCTION: We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthritis (RA). METHODS: The G1m genotypes were analyzed in three collections of patients with RA totaling 1037 subjects. The first, used for discovery, comprised 215 Spanish patients. The second and third were successively used for replication. They included 429 British and Greek patients and 393 Spanish and British patients, respectively. Two outcomes were considered: change in the Disease Activity Score in 28 joint (ΔDAS28) and the European League Against Rheumatism (EULAR) response criteria. RESULTS: An association between less response to INX and incompatibility of the G1m1,17 allotype was found in the discovery collection at 6 months of treatment (P = 0.03). This association was confirmed in the replications (P = 0.02 and 0.08, respectively) leading to a global association (P = 0.001) that involved a mean difference in ΔDAS28 of 0.4 units between compatible and incompatible patients (2.3 ± 1.5 in compatible patients vs. 1.9 ± 1.5 in incompatible patients) and an increase in responders and decrease in non-responders according to the EULAR criteria (P = 0.03). A similar association was suggested for patients treated with ADM in the discovery collection, but it was not supported by replication. CONCLUSIONS: Our results suggest that G1m1,17 allotypes are associated with response to INX and could aid improved therapeutic targeting in RA. 10.1186/s13075-015-0571-z 1478-6362 1478-6354 Arthritis research & therapy http://hdl.handle.net/10668/2176 25885039 http://hdl.handle.net/20.500.12105/17083 Artritis reumatoide Genotipo Articulaciones Enfermedades reumáticas Factor de necrosis tumoral alfa Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.